Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integration of genetic, clinical, and INR data to refine warfarin dosing.
Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF. Lenzini P, et al. Among authors: jorgensen al. Clin Pharmacol Ther. 2010 May;87(5):572-8. doi: 10.1038/clpt.2010.13. Epub 2010 Apr 7. Clin Pharmacol Ther. 2010. PMID: 20375999 Free PMC article.
Estimation of the warfarin dose with clinical and pharmacogenetic data.
International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. International Warfarin Pharmacogenetics Consortium, et al. N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329. N Engl J Med. 2009. PMID: 19228618 Free PMC article.
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.
Jorgensen AL, Al-Zubiedi S, Zhang JE, Keniry A, Hanson A, Hughes DA, Eker Dv, Stevens L, Hawkins K, Toh CH, Kamali F, Daly AK, Fitzmaurice D, Coffey A, Williamson PR, Park BK, Deloukas P, Pirmohamed M. Jorgensen AL, et al. Among authors: al zubiedi s. Pharmacogenet Genomics. 2009 Oct;19(10):800-12. doi: 10.1097/FPC.0b013e3283317ab5. Pharmacogenet Genomics. 2009. PMID: 19752777 Free PMC article. Clinical Trial.
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. Limdi NA, et al. Blood. 2010 May 6;115(18):3827-34. doi: 10.1182/blood-2009-12-255992. Epub 2010 Mar 4. Blood. 2010. PMID: 20203262 Free PMC article.
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M. Lane S, et al. Among authors: jorgensen al, al zubiedi s. Br J Clin Pharmacol. 2012 Jan;73(1):66-76. doi: 10.1111/j.1365-2125.2011.04051.x. Br J Clin Pharmacol. 2012. PMID: 21692828 Free PMC article.
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF. Horne BD, et al. Among authors: jorgensen al. Thromb Haemost. 2012 Feb;107(2):232-40. doi: 10.1160/TH11-06-0388. Epub 2011 Dec 21. Thromb Haemost. 2012. PMID: 22186998 Free PMC article.
183 results